Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?
Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?
复制标题
DOI：
10.1016/j.metabol.2016.01.013
复制
发表时间：
2016-08
期刊：
影响因子：
--
通讯作者：
Feldstein AE
中科院分区：
文献类型：
--
作者：
Alkhouri N;Feldstein AE
非酒精性脂肪性肝病（NAFLD）已迅速成为美国最常见的慢性肝病形式，影响约8000万至1亿美国人。NAFLD包括一系列疾病，从非酒精性脂肪肝（NAFL）到非酒精性脂肪性肝炎（NASH），再到纤维化和最终肝硬化。与NAFL患者相比，NASH和肝活检显示的显著纤维化患者的肝脏相关发病率和死亡率风险增加。由于NAFLD的高患病率及其进行性，迫切需要开发可靠的非侵入性测试，可以准确预测晚期疾病的存在，而无需肝活检。这些测试可以分为预测NASH存在的测试和预测纤维化存在的测试。在这篇综述中，我们提供了一个简明的概述不同的非侵入性方法分期的严重程度非酒精性脂肪肝。
Nonalcoholic fatty liver disease (NAFLD) has rapidly become the most common form of chronic liver disease in the United States affecting approximately 80–100 million Americans. NAFLD includes a spectrum of diseases ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH) to fibrosis and eventually cirrhosis. Patients with NASH and significant fibrosis on liver biopsy have an increased risk for liver-related morbidity and mortality compared to those with NAFL. Due to the high prevalence of NAFLD and its progressive nature, there has been an urgent need to develop reliable noninvasive tests that can accurately predict the presence of advanced disease without the need for liver biopsy. These tests can be divided into those that predict the presence of NASH and those that predict the presence of fibrosis. In this review, we provide a concise overview of different noninvasive methods for staging the severity of NAFLD.